Please login to the form below

Not currently logged in
Email:
Password:

Hikma

This page shows the latest Hikma news and features for those working in and with pharma, biotech and healthcare.

Amarin shares tumble following Vascepa patent loss

Amarin shares tumble following Vascepa patent loss

Dr Reddy’s Laboratories and Hikma Pharmaceuticals are already queueing up to launch generic versions of Vascepa, with Hikma reporting that it is working with the FDA to gain approval for

Latest news

More from news
Approximately 6 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • The human perspective The human perspective

    Chief among these moves were the German company's exit from the generics business, via a $2.6bn deal with specialty firm Hikma, and its forthcoming asset swap with Sanofi.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    348. Bedford Labs (Boehringer Ingelheim) / Hikma. Asset / product acquisition.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Hikma, the Jordanian generic company, acquired the assets of the US-based Bedford Labs (owned by Boehringer Ingelheim), a generic injectable manufacturer, for $300m (16 x sales). The price consists of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Hikma Pharmaceuticals appoints VP, sales and marketing, Generics. Kristy Ronco has been appointed as vice president, sales and marketing, generics for Hikma Pharmaceuticals. ... Ronco joins Hikma after more than a decade at Zydus Pharmaceuticals, where

  • Sigurdur Olafsson becomes CEO of Hikma Sigurdur Olafsson becomes CEO of Hikma

    As chief executive officer, Olafsson will take responsibility for the effective development and execution of Hikma’s corporate strategy, focusing on opportunities to accelerate growth of the global business. ... Said Darwazah, Hikma’s recently

  • Hikma appoints group scientific officer and global head of R&D Hikma appoints group scientific officer and global head of R&D

    Dr Surendera Tyagi joins the pharma group from Fresenius Kabi. Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr ... Surendera Tyagi, who will focus on the group’s non-injectables

More from appointments
Approximately 3 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics